Patient-reported outcomes essential to comparative effectiveness research

October 16, 2012

Patient-reported outcomes should be a standard part of evaluating the comparative effectiveness of cancer treatments, according to recommendations put forward by a multi-institution research group.

In an early release article published this week online in the , a research group led by Ethan Basch, MD, Director of the Outcomes Research Program at UNC Lineberger Comprehensive Cancer Center, recommends that patient-reported symptoms and health-related quality of life measures should be assessed in comparative effectiveness studies designed to generate new evidence about cancer treatment. The article was written on behalf of the Center for Medical Technology Policy in Baltimore, MD.

Comparative is designed to inform health-care decisions by providing evidence on the effectiveness, benefits, and harms of different treatment options. The evidence is generated from research studies that compare drugs, medical devices, tests, surgeries, or ways to deliver health care.

" research looks at how treatment options perform in a real-world setting, and is particularly important in , where patients are not only fighting their disease but also enduring treatments that may have a significant impact on their ability to function and their quality of life," said Basch.

"There is no way to adequately assess a treatment's impact on the patient without including their point of view, gleaned directly from asking about their experience in a consistent and scientifically-validated manner. Without this information, stakeholders – including patients, physicians and nurses, payers, researchers and regulators – have incomplete information for decision making about a given treatment."

The group recommends evaluation of a set of twelve core symptoms in studies in advanced or , use of standard, validated measurements for patient-reported outcomes, to identify specific symptoms that may be relevant in studies of treatment for particular forms of cancer, and methods to gather the relevant data efficiently and effectively.

Explore further: Strategies proposed to improve impact of comparative effectiveness studies

Related Stories

Strategies proposed to improve impact of comparative effectiveness studies

October 9, 2012
Comparative effectiveness research conducted over the past decade has had a limited impact on the way medical care is delivered, but many opportunities exist to help doctors and others in the medical system translate such ...

Complementary medicine not tied to prostate cancer outcome

May 4, 2012
(HealthDay) -- Although widely used, complementary and alternative medicine (CAM) does not impact patient satisfaction with treatment or patient-reported outcomes after treatment for localized prostate cancer, according to ...

Intensity Modulated Radiation Therapy optimal for localized prostate cancer

April 17, 2012
A treatment for localized prostate cancer known as Intensity Modulated Radiation Therapy (IMRT) is better than conventional conformal radiation therapy (CRT) for reducing certain side effects and preventing cancer recurrence, ...

Cancer survivorship research must look at quality of life: report

October 28, 2011
Assessing the quality of life experienced by cancer survivors is becoming increasingly important, say researchers at Moffitt Cancer Center in Tampa, Fla. Such an assessment has a number of important applications when doing ...

Recommended for you

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.